MAI Capital Management’s Gain Therapeutics GANX Stock Holding History

MAI Capital Management’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,410	Closed	-$14.2K	–	5073
2025 Q4	$14.2K	Hold	4,410	–	–	﹤0.01%	2693
2025 Q3	$7.81K	Hold	4,410	–	–	﹤0.01%	2845
2025 Q2	$7.94K	Hold	4,410	–	–	﹤0.01%	2849
2025 Q1	$8.42K	Hold	4,410	–	–	﹤0.01%	2558
2024 Q4	$9.53K	Buy	+4,410	New	+$8.85K	﹤0.01%	2530

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MAI Capital Management's GANX Position: Q1 2026 in Review

MAI Capital Management sold out of Gain Therapeutics (GANX) in Q1 2026, closing a stake of 4,410 shares — an estimated $14.2K sold.

MAI Capital Management first reported a position in GANX in Q4 2024 and held it in 5 quarters. The position peaked at $14.2K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

MAI Capital Management reported no remaining Gain Therapeutics position as of Q1 2026 after selling out during the quarter.
MAI Capital Management sold 4,410 Gain Therapeutics shares in Q1 2026, an estimated $14.2K.
MAI Capital Management first reported a position in Gain Therapeutics in Q4 2024 and held it in 5 quarters.
MAI Capital Management's Gain Therapeutics position peaked at $14.2K in Q4 2025.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.